Bariatric surgery is effective rescue strategy after GLP-1 receptor agonist failure

A study published in the Annals of Surgery on November 3, 2026, reveals that bariatric surgery can be an effective rescue strategy for individuals who have failed semaglutide or tirzepatide treatments for obesity. The research, led by Dr. Ali Aminian from the Cleveland Clinic, analyzed data on 4,661 adults with a BMI of 35 kg/m² or higher who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2018 and 2024. Of these, 61 discontinued semaglutide or tirzepatide, and 207 had inadequate weight loss response.

Before undergoing surgery, the estimated two-year medication-associated weight change was a 1.4% gain for those intolerant to the medication and a 1.5% total body weight loss for those with inadequate response. Following surgery, the two-year total body weight loss was significantly higher in both the intolerance and inadequate-response groups.

For those with intolerance, RYGB resulted in 27.9% and 22.7% weight loss for patients with and without type 2 diabetes, respectively, and 20.1% and 21.6% for RYGB and SG. In the inadequate-response group, RYGB led to 35.8% and 27.4% weight loss after RYGB, and 14.3% and 14.2% after SG. In comparison, the comparator group experienced 33.3% and 28.7% weight loss after RYGB and 23.6% and 19.9% after SG.

The study found that among the inadequate-response group, RYGB was associated with greater two-year total body weight loss than SG (32.7% versus 17.8%). Dr. Aminian stated, "GLP-1 medications have transformed obesity care, but they don't work for everyone. A growing number of patients and their doctors are asking: What's the next step? Our findings show that bariatric surgery can be that next step." However, two authors disclosed ties to the pharmaceutical industry.